For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, X4 Pharmaceuticals Inc’s stock clocked out at $1.43, down -4.03% from its previous closing price of $1.49. In other words, the price has decreased by -$4.03 from its previous closing price. On the day, 1.2 million shares were traded. XFOR stock price reached its highest trading level at $1.54 during the session, while it also had its lowest trading level at $1.38.
Ratios:
To gain a deeper understanding of XFOR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.58 and its Current Ratio is at 3.70. In the meantime, Its Debt-to-Equity ratio is 3.40 whereas as Long-Term Debt/Eq ratio is at 3.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 16 ’25 when Baldry Mark bought 1,032 shares for $2.48 per share. The transaction valued at 2,561 led to the insider holds 25,337 shares of the business.
Baldry Mark bought 13,404 shares of XFOR for $4,598 on Nov 15 ’24. The Chief Commercial Officer now owns 129,173 shares after completing the transaction at $0.34 per share. On Jan 24 ’25, another insider, Ragan Paula, who serves as the President and CEO of the company, sold 76,473 shares for $0.45 each. As a result, the insider received 34,719 and left with 1,087,386 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 10265626 and an Enterprise Value of 2088503. As of this moment, X4’s Price-to-Earnings (P/E) ratio for their current fiscal year is 0.64. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26 while its Price-to-Book (P/B) ratio in mrq is 0.36. Its current Enterprise Value per Revenue stands at 0.067 whereas that against EBITDA is -0.019.
Stock Price History:
The Beta on a monthly basis for XFOR is 0.60, which has changed by -0.9401924 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $26.96, while it has fallen to a 52-week low of $1.40. The 50-Day Moving Average of the stock is -47.14%, while the 200-Day Moving Average is calculated to be -86.65%.
Shares Statistics:
It appears that XFOR traded 396.54K shares on average per day over the past three months and 981140 shares per day over the past ten days. A total of 5.79M shares are outstanding, with a floating share count of 3.84M. Insiders hold about 33.66% of the company’s shares, while institutions hold 29.13% stake in the company. Shares short for XFOR as of 1749772800 were 484831 with a Short Ratio of 0.95, compared to 1747267200 on 312303. Therefore, it implies a Short% of Shares Outstanding of 484831 and a Short% of Float of 8.5.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
X4 Pharmaceuticals Inc (XFOR) is currently under the scrutiny of 3.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$3.02, with high estimates of -$1.11 and low estimates of -$4.44.
Analysts are recommending an EPS of between -$5.03 and -$12.78 for the fiscal current year, implying an average EPS of -$9.62. EPS for the following year is -$12.23, with 3.0 analysts recommending between -$3.28 and -$17.51.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $1.62M. It ranges from a high estimate of $2.06M to a low estimate of $1.44M. As of the current estimate, X4 Pharmaceuticals Inc’s year-ago sales were $563kFor the next quarter, 5 analysts are estimating revenue of $2.06M. There is a high estimate of $2.4M for the next quarter, whereas the lowest estimate is $1.75M.
A total of 5 analysts have provided revenue estimates for XFOR’s current fiscal year. The highest revenue estimate was $36.5M, while the lowest revenue estimate was $33.95M, resulting in an average revenue estimate of $35.11M. In the same quarter a year ago, actual revenue was $2.56MBased on 6 analysts’ estimates, the company’s revenue will be $22.83M in the next fiscal year. The high estimate is $34.2M and the low estimate is $10.3M.
